Accelrys stays on growth track in Q4

Accelrys ($ACCL) has bested analysts' estimates on the San Diego company's revenue for the fourth quarter. The provider of lab software for biopharma groups recorded $39.8 million in quarterly revenue--better than the $38.7 million analysts had predicted, Daily Finance reports. Accelrys has seen its overall growth accelerate in recent years through a series of buyouts of companies such as Symyx, Contur and VelQuest. Report

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.